Concepedia

Raymond A. Bendele

RA

Statistics

Publications

12

Citations

1.3K

H-Index

12

Active since

1992

Affiliations

Eli Lilly (United States)(Current)

Gilead Sciences (United States)

Nivalis Therapeutics (United States)

Raymond A. Bendele is an author at Eli Lilly (United States) specializing in pharmacology, pharmacy, and toxicology.

Publications per year

1992–2004

12

Publications

12

Raloxifene (LY139481 HCI) prevents bone loss and reduces serum cholesterol without causing uterine hypertrophy in ovariectomized rats.

Larry J. Black, Masahiko Sato, Ellen R. Rowley et al. · Journal of Clinical Investigation · 1994 · 613 citations · Full text

, , +17

Pharmacokinetics and Safety of an Anti-Vascular Endothelial Growth Factor Aptamer (NX1838) Following Injection into the Vitreous Humor of Rhesus Monkeys

Daniel W. Drolet, J. Arly Nelson, Christopher E. Tucker et al. · Pharmaceutical Research · 2000 · 204 citations

, , +14

Derivation of RNA aptamer inhibitors of human complement C5

G Biesecker, Larry Dihel, Kristin Enney et al. · Immunopharmacology · 1999 · 150 citations

, , +12

Carcinogenicity studies of fluoxetine hydrochloride in rats and mice.

Raymond A. Bendele, Elizabeth R. Adams, Wherly P. Hoffman et al. · PubMed · 1992 · 76 citations

, , +14

Antitumor efficacy, pharmacokinetics, and biodistribution of NX 211: a low-clearance liposomal formulation of lurtotecan.

David L. Emerson, Raymond A. Bendele, Eric Brown et al. · PubMed · 2000 · 61 citations

, , +13

1–5 of 12